# Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy

> **NCT00888082** · PHASE3 · WITHDRAWN · sponsor: **AstraZeneca** · enrollment: 102 (estimated)

## Conditions studied

- Breast Cancer
- Ovarian Function

## Interventions

- **DRUG:** Goserelin acetate

## Key facts

- **NCT ID:** NCT00888082
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2010-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00888082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00888082, "Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00888082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*